# Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

> **NCT05241860** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 79 (actual)

## Conditions studied

- Castration-Sensitive Prostate Carcinoma
- Metastatic Prostate Carcinoma
- Stage IV Prostate Cancer AJCC v8
- Stage IVA Prostate Cancer AJCC v8
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **OTHER:** Pharmacotherapy Discontinuation
- **OTHER:** Follow-Up
- **OTHER:** Questionnaire Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT05241860
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-21
- **Primary completion:** 2025-09-29
- **Final completion:** 2033-09-01
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05241860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05241860, "Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05241860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*